Characterization of niphatenones that inhibit androgen receptor n-terminal domain

PLoS ONE

Volumn 9, Issue 9, 2014, Pages

  Banuelos, Carmen A ^a   Lal, Aaron ^a   Tien, Amy H ^a   Shah, Neel ^a   Yang, Yu Chi ^a   Mawji, Nasrin R ^a   Meimetis, Labros G ^b   Park, Jacob ^a   Kunzhong, Jian ^a   Andersen, Raymond J ^b   Sadar, Marianne D ^a  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; ANTINEOPLASTIC AGENT; BICALUTAMIDE; ENZALUTAMIDE; EPI 002; GLUCOCORTICOID RECEPTOR; GLUTATHIONE; GLYCEROL DERIVATIVE; NATURAL PRODUCT; NIPHATENONE B; NIPHATENONE DERIVATIVE; PROGESTERONE RECEPTOR; PROTEIN VARIANT; UNCLASSIFIED DRUG; ANDROGEN RECEPTOR ANTAGONIST; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; GLYCEROL ETHER; METRIBOLONE;

ALKYLATION; AMINO TERMINAL SEQUENCE; ANIMAL CELL; ARTICLE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DRUG PROTEIN BINDING; ENANTIOMER; HUMAN; HUMAN CELL; IC50; NONHUMAN; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN LOCALIZATION; RECEPTOR BLOCKING; TRANSACTIVATION; CHEMISTRY; DRUG EFFECTS; MALE; PHYSIOLOGY; PROSTATIC NEOPLASMS; PROTEIN TERTIARY STRUCTURE; STEREOISOMERISM; TRANSCRIPTION INITIATION; TUMOR CELL LINE;

ANDROGEN RECEPTOR ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; CELL LINE, TUMOR; GLYCERYL ETHERS; HUMANS; INHIBITORY CONCENTRATION 50; MALE; METRIBOLONE; PROSTATIC NEOPLASMS; PROTEIN STRUCTURE, TERTIARY; RECEPTORS, ANDROGEN; STEREOISOMERISM; TRANSCRIPTIONAL ACTIVATION;

EID: 84907551904     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.010799     Document Type: Article

References (28)

1. McEwan IJ (2012) Intrinsic disorder in the androgen receptor: identification, characterisation and drugability. Mol Biosyst 8: 82-90.
2. Sadar MD (2011) Small molecule inhibitors targeting the ''achilles' heel'' of androgen receptor activity. Cancer Res 71: 1208-1213.
3. Andersen RJ, Mawji NR, Wang J, Wang G, Haile S, et al. (2010) Regression of castrate-recurrent prostate cancer by a small-molecule inhibitor of the aminoterminus domain of the androgen receptor. Cancer Cell. 17: 535-546.
4. Myung JK, Banuelos CA, Fernandez JG, Mawji NR, Wang J, et al. (2013) An androgen receptor N-terminal domain antagonist for treating prostate cancer. J Clin Invest 123: 2948-2960.
5. Sadar MD, Williams DE, Mawji NR, Patrick BO, Wikanta T, et al. (2008) Sintokamides A to E, chlorinated peptides from the sponge Dysidea sp. that inhibit transactivation of the N-terminus of the androgen receptor in prostate cancer cells. Org Lett 10: 4947-50.
6. Meimetis LG, Williams DE, Mawji NR, Banuelos CA, Lal AA, et al. (2012) Niphatenones, glycerol ethers from the sponge Niphates digitalis block androgen receptor transcriptional activity in prostate cancer cells: structure elucidation, synthesis, and biological activity. J Med Chem 55: 503-514.
7. Sun S, Sprenger CC, Vessella RL, Haugk K, Soriano K, et al. (2010) Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant. J Clin Invest 120: 2715-2730.
8. Romanuik TL, Ueda T, Le N, Haile S, Yong TM, et al. (2009a) Novel biomarkers for prostate cancer including noncoding transcripts. Am J Pathol 175: 2264-2276.
9. Romanuik TL, Wang G, Holt RA, Jones SJ, Marra MA, et al. (2009b) Identification of novel androgen-responsive genes by sequencing of LongSAGE libraries. BMC Genomics 10: 476.
10. Jenster G, van der Korput HA, van Vroonhoven C, van der Kwast TH, Trapman J, et al. (1991) Domains of the human androgen receptor involved in steroid binding, transcriptional activation, and subcellular localization. Mol Endocrinol 5: 1396-1404.
11. Quayle SN, Mawji NR, Wang J, Sadar MD (2007) Androgen receptor decoy molecules block the growth of prostate cancer. Proc Natl Acad Sci U S A 104: 1331-1336.
12. Simental JA, Sar M, Lane MV, French FS, Wilson EM (1991) Transcriptional activation and nuclear targeting signals of the human androgen receptor. J Biol Chem 266: 510-518.
13. Rundlett SE, Wu XP, Miesfeld RL (1990) Functional characterizations of the androgen receptor confirm that the molecular basis of androgen action is transcriptional regulation. Mol Endocrinol 4: 708-714.
14. Langley E, Kemppainen JA, Wilson EM (1998) Intermolecular NH2-/carboxylterminal interactions in androgen receptor dimerization revealed by mutations that cause androgen insensitivity. J BIol Chem 273: 92-101.
15. He B, Kemppainen JA, Voegel JJ, Gronemeyer H, Wilson EM (1999) Activation function 2 in the human androgen receptor ligand binding domain mediates interdomain communication with the NH(2)-terminal domain. J Biol Chem 274: 37219-37225.
16. Tran C, Ouk S, Clegg NJ, Chen Y, Watson PA, et al. (2009) Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 324: 787-790.
17. Masiello D, Cheng S, Bubley GJ, Lu ML, Balk SP (2002) Bicalutamide functions as an androgen receptor antagonist by assembly of a transcriptionally inactive receptor. J Biol Chem 277: 26321-26326.
18. Clegg NJ, Wongvipat J, Joseph JD, Tran C, Ouk S, et al. (2012) ARN-509: a novel antiandrogen for prostate cancer treatment. Cancer Res 72: 1494-1503.
19. He B, Bai S, Hnat AT, Kalman RI, Minges JT, et al. (2004) An androgen receptor NH-terminal conserved motif interacts with the COOH terminus of the Hsp70-interacting Protein (CHIP). J Biol Chem 279: 30643-30653.
20. Lavery DN, McEwan (2005) Structure and function of steroid receptor AF1 transactivation domains: induction of active conformations. Biochem J 391: 449-464.
21. McEwan IJ, Lavery D, Fischer K, Watt K (2007) Natural disordered sequences in the amino terminal domain of nuclear receptors: lessons from the androgen and glucocorticoid receptors. Nucl Recept Signal 5: e001.
22. Zhang X, Morrissey C, Sun S, Ketchandji M, Nelson PS, et al. (2011) Androgen receptor variants occur frequently in castration resistant prostate cancer metastases. PLoS One. 6: e27970.
23. Mostaghel EA, Marck BT, Plymate SR, Vessella RL, Balk S, et al. (2011) Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: induction of steroidogenesis and androgen receptor splice variants. Clin Cancer Res 17: 5913-5925.
24. Heemers HV, Tindall DJ (2007) Androgen receptor (AR) coregulators: a diversity of functions converging on and regulating the AR transcriptional complex. Endocr Rev 28: 778-808.
25. Zhou ZX, Lane MV, Kemppainen JA, French FS, Wilson EM (1995) Specificity of ligand-dependent androgen receptor stabilization: receptor domain interactions influence ligand dissociation and receptor stability. Mol Endocrino l 9: 208-218.
26. Langley E, Zhou ZX, Wilson EM (1995) Evidence for an anti-parallel orientation of the ligand-activated human androgen receptor dimer. J Biol Chem 270: 29983-29990.
27. He B, Kemppainen JA, Wilson EM (2000) FXXLF and WXXLF sequences mediate the NH2-terminal interaction with the ligand binding domain of the androgen receptor. J Biol Chem 275: 22986-22994.
28. Hornberg E, Ylitalo EB, Crnalic S, Antti H, Stattin P, et al. (2011) Expression of androgen receptor splice variants in prostate cancer bone metastases is associated with castration-resistance and short survival. PLoS One 6: e19059.